- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03761043
Nurse Promotion of IV to PO Antimicrobial Conversion (FERN-IPO)
5. september 2019 oppdatert av: Sean Gorman, Kelowna General Hospital
Fostering Engagement From Nurses in Promoting IV to PO Antimicrobial Conversion: The FERN-IPO Study
This is a prospective, quasi-experimental, historically controlled study to evaluate if a behavioural change intervention informed by the COM-B model of behaviour change can improve nurses' self-perceived capability, opportunity, and motivation to engage in the assessment of patients who may be appropriate for IV to PO antimicrobial conversion.
This study also seeks to determine if this translates into an increase in IV to PO antimicrobial conversion rates in the acute care setting.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
Current antimicrobial stewardship guidelines recommend appropriate and timely IV to PO antimicrobial conversion in hospitalized patients.
Published rates of IV to PO antimicrobial conversion are consistently below 50% in eligible inpatients.
Studies have suggested that nurses may be well positioned to provide a positive influence on prescriber behavior related to antimicrobial IV to PO conversion, however, no published research has evaluated the impact of nurses on antimicrobial IV to PO conversion rates.
Published research has described the barriers and enablers to nurse participation in promoting antimicrobial IV to PO conversion using the COM-B model of behaviour change.
This quasi-experimental study will evaluate whether determinants of nurse behaviour and their actual behaviour can be changed to increase antimicrobial IV to PO conversion rates in hospitalized patients.
Studietype
Intervensjonell
Registrering (Faktiske)
853
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y1T2
- Kelowna General Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
19 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Nineteen years of age or older
- Employed as a RN or LPN at KGH in any capacity (full-time, part-time or casual employee)
- Practicing on a medicine/thoracic surgery ward (4A) or medicine/oncology/respiratory ward (4B)
Exclusion Criteria:
- RNs or LPNs on orientation shifts/training
- RNs or LPNs not engaged in patient care
- Student nurses/nurses in training
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Pre-Intervention Arm
The nurses will have not been exposed to the behavior change intervention.
|
|
|
Eksperimentell: Post-Intervention Arm
The nurses will have been exposed to the behavior change intervention.
|
IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
IV to PO antimicrobial conversion rate
Tidsramme: Six months (three months pre-intervention, three months post-intervention)
|
Incidence of IV to PO antimicrobial conversion (defined as the initiation of a PO antimicrobial within 24 hours of discontinuation of an IV antimicrobial during a single treatment course in a specific patient) before and after behavior change intervention
|
Six months (three months pre-intervention, three months post-intervention)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Days of IV therapy prior to conversion to PO antimicrobial
Tidsramme: Six months (three months pre-intervention, three months post-intervention)
|
For treatment courses that undergo IV to PO antimicrobial conversion, the days of IV antimicrobial therapy prior to PO conversion before and after intervention
|
Six months (three months pre-intervention, three months post-intervention)
|
|
Nurse perceptions of capability, opportunity and motivation to promote IV to PO antimicrobial conversion
Tidsramme: Six months (three months pre-intervention, three months post-intervention)
|
Constructs are derived using the Theoretical Domains Framework and assess nurse perceived capability, motivation, and opportunity to promote IV to PO antimicrobial conversion using a 7-point Likert scale (1 - Strongly Disagree, 2 - Disagree, 3- Slightly Disagree, 4 - Neither Agree or Disagree, 5 - Slightly Agree, 6 - Agree, 7- Strongly Agree).
The average Likert scale score for each of nine constructs (based on the Theoretical Domains Framework) will be calculated for the pre-intervention period and the post-intervention period.
Change in the average Likert score for each construct (question) in the pre-intervention period versus the post-intervention period will be compared for each construct.
A higher average Likert score on a construct in the post-intervention period compared to the pre-intervention period indicates improved perceptions about capability, opportunity, or motivation to promote IV to PO antimicrobial conversion.
|
Six months (three months pre-intervention, three months post-intervention)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Balancing measure - Failed IV to PO antimicrobial conversion
Tidsramme: Six months (three months pre-intervention, three months post-intervention
|
Incidence of failed IV to PO antimicrobial conversion (defined as the re-initiation of an IV antimicrobial within seven days following IV to PO conversion of an antimicrobial during a single treatment course for a specific patient) pre and post-intervention
|
Six months (three months pre-intervention, three months post-intervention
|
|
Subgroup Analysis 1: Nursing Unit Conversion Comparison
Tidsramme: Six months (three months pre-intervention, three months post-intervention)
|
Incidence of IV to PO antimicrobial conversion on nursing unit 1 (contains a clinical pharmacist) versus nursing unit 2 (does not contain a clinical pharmacist) pre and post-intervention
|
Six months (three months pre-intervention, three months post-intervention)
|
|
Subgroup Analysis 2: High Bioavailability Antimicrobial Conversion
Tidsramme: Six months (three months pre-intervention, three months post-intervention)
|
Incidence of IV to PO antimicrobial conversion for highly bioavailable (F ≥ 80%) antimicrobials pre and post-intervention
|
Six months (three months pre-intervention, three months post-intervention)
|
|
Subgroup Analysis 2: Non-High Bioavailability Antimicrobial Conversion
Tidsramme: Six months (three months pre-intervention, three months post-intervention)
|
Incidence of IV to PO antimicrobial conversion for non-highly bioavailable (F < 80%) antimicrobials pre and post-intervention
|
Six months (three months pre-intervention, three months post-intervention)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Victoria Cox, PharmD, Interior Health Authority
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
8. januar 2019
Primær fullføring (Faktiske)
7. april 2019
Studiet fullført (Faktiske)
7. april 2019
Datoer for studieregistrering
Først innsendt
29. november 2018
Først innsendt som oppfylte QC-kriteriene
29. november 2018
Først lagt ut (Faktiske)
3. desember 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
6. september 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
5. september 2019
Sist bekreftet
1. september 2019
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IH1803202
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .